Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Apixaban
Drug ID BADD_D00151
Description Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012[L6043].
Indications and Usage Apixaban is indicated for reducing the risk of stroke and systemic embolism in patients who have nonvalvular atrial fibrillation, prophylaxis of deep vein thrombosis(DVT) leading to pulmonary embolism(PE) in patients after a hip or knee replacement surgery, and treatment of DVT and PE to reduce the risk of recurrence[Label,A177565,A6897].
Marketing Status approved
ATC Code B01AF02
DrugBank ID DB06605
KEGG ID D03213
MeSH ID C522181
PubChem ID 10182969
TTD Drug ID D0I5HF
NDC Product Code 0003-0893; 52048-0420; 69037-0023; 76397-007; 15308-1221; 24196-190; 58032-2028; 66174-0091; 50193-0893; 65372-1196; 65727-081; 0003-3764; 55154-0612; 59651-051; 70366-001; 14445-149; 12783-0893; 12783-0894; 17381-026; 42765-025; 42816-0894; 58623-0137; 63850-8085; 65129-1344; 66039-925; 66651-921; 69989-0006; 63629-7747; 12658-0440; 53869-0893; 73377-191; 55154-0613; 70518-1861; 71610-662; 67835-0015; 75945-060; 76397-010; 50090-6454; 82982-054; 14501-0089; 16436-0113; 65129-1465; 63629-8432; 14445-014; 53747-062; 53869-0894; 63415-0520; 65015-897; 76072-1017; 14445-150; 42816-0893; 0003-0894; 55111-980; 50090-6451
UNII 3Z9Y7UWC1J
Synonyms apixaban | Eliquis | BMS 562247 | BMS562247 | BMS-562247-01 | BMS-562247
Chemical Information
Molecular Formula C25H25N5O4
CAS Registry Number 503612-47-3
SMILES COC1=CC=C(C=C1)N2C3=C(CCN(C3=O)C4=CC=C(C=C4)N5CCCCC5=O)C(=N2)C(=O)N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Dieulafoy's vascular malformation24.03.03.025; 07.15.04.0020.000087%Not Available
Haemorrhagic hepatic cyst16.06.02.003; 09.01.08.013; 24.07.01.0700.000239%Not Available
Cerebral amyloid angiopathy17.08.02.017; 10.02.05.003; 24.03.05.0100.000217%Not Available
Cardiorenal syndrome20.01.03.018; 02.05.01.0120.000043%Not Available
Capillaritis24.12.04.004; 23.06.02.0070.000043%Not Available
Cerebellar ischaemia24.04.06.033; 17.08.01.0470.000043%Not Available
Basal ganglia infarction24.04.06.028; 17.08.01.040--Not Available
Gastrointestinal vascular malformation24.03.03.031; 07.15.04.0070.000087%Not Available
Seizure like phenomena17.12.03.0300.000065%Not Available
Mesenteric haematoma12.01.17.013; 24.07.02.049; 07.12.03.0080.000043%Not Available
Ophthalmic vein thrombosis24.01.05.011; 06.07.02.0070.000043%Not Available
Gastrointestinal polyp haemorrhage16.05.01.008; 24.07.02.046; 07.20.01.0110.000065%Not Available
Spontaneous haemorrhage01.01.03.007; 24.07.01.0810.000260%Not Available
Oral mucosa haematoma07.05.02.003; 24.07.02.0530.000065%Not Available
Internal haemorrhage24.07.01.0720.002560%Not Available
Cerebral ventricular rupture17.11.01.014; 12.01.10.0150.000347%Not Available
Fine motor skill dysfunction17.01.02.020--Not Available
Gluten sensitivity07.17.01.009; 14.02.01.008; 10.01.01.0310.000148%Not Available
Lacunar stroke24.04.06.037; 17.08.01.0540.000065%Not Available
Vein rupture24.03.02.032; 12.01.11.0110.000130%Not Available
Oesophageal intramural haematoma24.07.02.050; 07.12.01.0060.000043%Not Available
End stage renal disease20.01.03.0190.000239%Not Available
Intracranial mass17.11.01.0170.000130%Not Available
Tongue discomfort07.14.02.019--Not Available
Abortion early18.01.01.0060.000043%Not Available
Acquired antithrombin III deficiency01.01.01.0130.000043%Not Available
Allergic reaction to excipient10.01.01.0350.000148%Not Available
Antisynthetase syndrome10.04.04.019; 22.01.02.027; 15.05.01.0100.000065%Not Available
Atheroembolism24.01.01.037; 12.02.05.0520.000239%Not Available
Basal ganglia haematoma24.07.04.035; 17.08.01.0650.000043%Not Available
The 24th Page    First    Pre   24 25 26    Next   Last    Total 26 Pages